At a recent meeting in Boston, representatives from global pharmaceutical companies gathered to discuss how to transition from batch to continuous manufacturing. And what company better to learn from ...

Although estimates vary slightly, many industry experts predict continuous manufacturing will, at the least, cut the cost of manufacturing biologics in half. Thus, it will be an attractive option for ...

A handful of companies have done pioneering work with continuous manufacturing, the production process that is faster, cheaper and less prone to the kinds of manufacturing mess-ups that worry the FDA.

Continuous manufacturing makes monoclonal antibody production faster, cheaper, and greener, say researchers, who predict that industry adoption of the approach will accelerate in response to ...

The biopharmaceutical industry has seen substantial growth in recent years, generating novel biotherapeutics and biosimilars at an unprecedented rate. One of the biggest challenges in the industry is ...

Continuous manufacturing offers advantages in both biotherapeutic and API manufacturing but still poses challenges. The forward movement of the bio/pharmaceutical industry is driven by fast-paced ...

The pharmaceutical industry has been slow to adopt a business practice that is faster, safer, and more efficient than its current way of operating; that the FDA has been encouraging the industry to ...

“It’s called a BHAG,” says Hayden Thomas, divulging a term popular among chemical engineers at Vertex Pharmaceuticals, where Thomas is vice president of formulation development. “A big, hairy, ...

DIANT is a startup co-founded by Antonio Costa, Ph.D. and Diane Burgess, Ph.D. In 2020, DIANT licensed their core manufacturing technology from UConn and was granted a patent on the technology earlier ...

The move towards “pharma 4.0” requires a major shift, both ideologically and technologically, to adapt current processes to a framework that will automate much of today’s manufacturing. One of the ...